Oncologypipeline

Oncologypipeline company information, Employees & Contact Information

Explore related pages

Related company profiles:

OncologyPipeline is a comprehensive online resource tool that maps all relevant clinical trials and molecules in development in Oncology on a worldwide basis. OncologyPipeline allows you, amongst other things, to know what registrational trials and strategies the different companies are pursuing and which product or indication will be launched in the near future or in the years to come. Projects can be searched by tumor, company, line of treatment, original brand / biosimilar and many variables more. Furthermore, you can retrieve all relevant results, abstracts and publications from congresses such as ASCO, ESMO, EHA, ASH etc. OncologyPipeline is very fast, intuitive and will save you a lot of time!

Company Details

Employees
27
Founded
-
Address
C/ Castelló, 59, Madrid,spain 28001,spain
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
Madrid, Spain
Looking for a particular Oncologypipeline employee's phone or email?

Oncologypipeline Questions

News

ESMO 2025 – Celcuity fights for a share of the breast cancer market | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

ESMO 2025 – Celcuity fights for a share of the breast cancer market | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Astra pulls further ahead of Merck’s Curon project | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Astra pulls further ahead of Merck’s Curon project | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

ESMO 2025 – Incyte impresses in KRAS G12D | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

ESMO 2025 – Incyte impresses in KRAS G12D | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Astellas and Amgen join the pan-KRAS push | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Astellas and Amgen join the pan-KRAS push | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Pfizer pushes a non-metastatic prostate survival edge | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Pfizer pushes a non-metastatic prostate survival edge | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Bristol pulls ahead of Amgen | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Bristol pulls ahead of Amgen | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Pfizer starts its PD-L1 conjugate with lung first | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Pfizer starts its PD-L1 conjugate with lung first | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Astra's clash of the T-cell engager Titans | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Astra's clash of the T-cell engager Titans | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

5,000 patients later Roche scraps its TIGIT | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

5,000 patients later Roche scraps its TIGIT | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

World Lung 2025 – Candel looks to a new agla-vec use | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

World Lung 2025 – Candel looks to a new agla-vec use | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Not the zanza trial some were looking for | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Not the zanza trial some were looking for | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Unharmonious ivonescimab reveal for Summit | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Unharmonious ivonescimab reveal for Summit | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Kura joins the pivotal menin push | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Kura joins the pivotal menin push | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

AbbVie reveals its bispecific interest | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

AbbVie reveals its bispecific interest | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Lyell takes on J&J and Gilead | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Lyell takes on J&J and Gilead | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

iTeos, and Roche's RAS mystery, start phase 1 | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

iTeos, and Roche's RAS mystery, start phase 1 | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

ASCO 2025 preview – Kura looks similar to Syndax | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

ASCO 2025 preview – Kura looks similar to Syndax | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Bristol exits KRAS G12D | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Bristol exits KRAS G12D | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

ASCO 2025 – Astra seeks a new SERD paradigm | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

ASCO 2025 – Astra seeks a new SERD paradigm | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Amgen and Zai Lab eye a gastric niche | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Amgen and Zai Lab eye a gastric niche | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

ADC molecules deciphered | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

ADC molecules deciphered | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

AstraZeneca doubles down on GPC3 | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

AstraZeneca doubles down on GPC3 | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

T-cell engagement with a difference | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

T-cell engagement with a difference | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Another TIGIT bites the dust | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Another TIGIT bites the dust | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

World Lung 2025 – pumitamig confirms its small-cell promise | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

World Lung 2025 – pumitamig confirms its small-cell promise | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

ASCO 2025 – Trodelvy heads for the front line | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

ASCO 2025 – Trodelvy heads for the front line | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Nuvalent sets out its two-pronged strategy | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Nuvalent sets out its two-pronged strategy | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Regeneron enters the T-cell engager arena | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Regeneron enters the T-cell engager arena | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

More problems for BioNTech & Roche’s neoantigen shot | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

More problems for BioNTech & Roche’s neoantigen shot | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

ASCO 2025 – Astellas's new Claudin18.2 interest | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

ASCO 2025 – Astellas's new Claudin18.2 interest | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

ASCO 2025 – Enhertu mounts its first-line charge | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

ASCO 2025 – Enhertu mounts its first-line charge | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

ASCO 2025 – Exelixis’s son of Cabometyx improves | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

ASCO 2025 – Exelixis’s son of Cabometyx improves | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

A bispecific encore, plus two in vivo Cars | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

A bispecific encore, plus two in vivo Cars | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Lantheus calls time on me-too Pluvicto | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Lantheus calls time on me-too Pluvicto | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

AACR 2025 preview – a surge in dual-payload conjugates | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

AACR 2025 preview – a surge in dual-payload conjugates | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Vepdegestrant’s promise narrows | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Vepdegestrant’s promise narrows | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

BeiGene remains bold with sonrotoclax | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

BeiGene remains bold with sonrotoclax | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

ASCO 2025 preview – late-breakers in focus | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

ASCO 2025 preview – late-breakers in focus | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Ivonescimab takes on pancreatic cancer | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Ivonescimab takes on pancreatic cancer | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Otsuka bids for a seat at the conjugate table | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Otsuka bids for a seat at the conjugate table | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Elevation goes down on Claudin disaster | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Elevation goes down on Claudin disaster | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

SystImmune spreads into first-line lung | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

SystImmune spreads into first-line lung | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

DLL3 goes trispecific | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

DLL3 goes trispecific | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

AACR 2025 preview – new preclincal approaches abound | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

AACR 2025 preview – new preclincal approaches abound | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Halozyme pushes to add Merck to its subQ partners | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Halozyme pushes to add Merck to its subQ partners | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Merck and Daiichi look for more ifinatamab white space | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Merck and Daiichi look for more ifinatamab white space | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

GSK hatches pivotal Hansoh conjugate plans | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

GSK hatches pivotal Hansoh conjugate plans | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

J&J catches its menin rivals | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

J&J catches its menin rivals | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

ELCC 2025 – BioNTech impresses in small-cell lung | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

ELCC 2025 – BioNTech impresses in small-cell lung | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Regeneron’s Met bet falls short | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Regeneron’s Met bet falls short | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Novartis gets a PSMAfore green flag at last | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Novartis gets a PSMAfore green flag at last | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

ITM hopes to Compete against Lutathera | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

ITM hopes to Compete against Lutathera | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Pivotal study designs revealed | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Pivotal study designs revealed | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Orca heads to the FDA | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Orca heads to the FDA | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Janux impresses again | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Janux impresses again | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Two more reasons for GSK to be wary of Tim-3 | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Two more reasons for GSK to be wary of Tim-3 | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Innate challenges Pfizer in Nectin-4 | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Innate challenges Pfizer in Nectin-4 | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

CytomX shifts towards EpCAM | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

CytomX shifts towards EpCAM | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

KAT6 catalysts to kick off 2025 | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

KAT6 catalysts to kick off 2025 | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

More bad vibes kill off Merck’s TIGIT and Lag3 | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

More bad vibes kill off Merck’s TIGIT and Lag3 | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Another pan-KRAS project enters the clinic | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Another pan-KRAS project enters the clinic | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Conjugates enter their first clinical trials - Oncology Pipeline

Conjugates enter their first clinical trials Oncology Pipeline

ASH 2024 – AbbVie fights to rise above the BCMA crowd | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

ASH 2024 – AbbVie fights to rise above the BCMA crowd | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

ASH 2024 – Sumitomo joins the menin party | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

ASH 2024 – Sumitomo joins the menin party | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Roche’s Skyscraper crumbles | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Roche’s Skyscraper crumbles | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

ASH 2024 preview – more challenges to the BTK order | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

ASH 2024 preview – more challenges to the BTK order | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

ASH 2024 preview – multiple myeloma in focus | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

ASH 2024 preview – multiple myeloma in focus | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Merck & Co gets in on the bispecific act | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Merck & Co gets in on the bispecific act | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

ASH 2024 preview – menin inhibitors face off again | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

ASH 2024 preview – menin inhibitors face off again | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Transgene stumbles with its fixed immunotherapy | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Transgene stumbles with its fixed immunotherapy | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

BeiGene takes a new approach to a hot target | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

BeiGene takes a new approach to a hot target | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Where next for TIGIT? | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Where next for TIGIT? | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Fresh questions over DLL3 | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Fresh questions over DLL3 | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

ESMO 2024 – degraders disappoint again | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

ESMO 2024 – degraders disappoint again | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Merck seeks the next Keytruda | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Merck seeks the next Keytruda | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Claudin18.2 expression clouds Elevation's big reveal | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Claudin18.2 expression clouds Elevation's big reveal | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Lilly is down but not out of PI3K alpha inhibition | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Lilly is down but not out of PI3K alpha inhibition | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

World Lung 2024 – backing for ifinatamab’s pivotal move | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

World Lung 2024 – backing for ifinatamab’s pivotal move | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Syndax hit by menin delay | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Syndax hit by menin delay | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Merck’s subQ Keytruda headscratcher | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Merck’s subQ Keytruda headscratcher | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Roche reins in the TIGIT expectations | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Roche reins in the TIGIT expectations | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

iTeos’s TIGIT goes pivotal at last | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

iTeos’s TIGIT goes pivotal at last | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Bristol makes a quick pivotal move in multiple myeloma | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Bristol makes a quick pivotal move in multiple myeloma | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

ESMO 2024 – Astra’s B7-H4 effort underwhelms | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

ESMO 2024 – Astra’s B7-H4 effort underwhelms | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Opdualag sets its sights on lung | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Opdualag sets its sights on lung | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Merck joins the TIGIT pivotal failure club | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Merck joins the TIGIT pivotal failure club | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

ASCO 2024 – AstraZeneca’s GPC3 secret sauce | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

ASCO 2024 – AstraZeneca’s GPC3 secret sauce | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Merck and Daiichi look beyond small cell with ifinatamab | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Merck and Daiichi look beyond small cell with ifinatamab | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

ESMO 2024 preview – Summit could take on Merck in breast cancer | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

ESMO 2024 preview – Summit could take on Merck in breast cancer | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

CCR8 expectations | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

CCR8 expectations | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Astra bets on an EGFR future beyond Tagrisso | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Astra bets on an EGFR future beyond Tagrisso | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Ipsen casts doubt on Pfizer’s prostate plan | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Ipsen casts doubt on Pfizer’s prostate plan | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

ESMO 2024 preview – conjugates in the spotlight | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

ESMO 2024 preview – conjugates in the spotlight | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

ASCO 2024 – Pfizer’s KAT6 inhibitor purrs | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

ASCO 2024 – Pfizer’s KAT6 inhibitor purrs | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Triple meeting 2024 – can Revolution succeed where others stumbled? | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Triple meeting 2024 – can Revolution succeed where others stumbled? | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

ESMO 2024 preview – Summit and BioNTech battle again | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

ESMO 2024 preview – Summit and BioNTech battle again | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

BeiGene tries where others failed | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

BeiGene tries where others failed | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Bicara chases Merus | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Bicara chases Merus | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Bristol backs out of BET inhibition | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Bristol backs out of BET inhibition | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

ASCO 2024 – Summit peaks on ivonescimab surprise | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

ASCO 2024 – Summit peaks on ivonescimab surprise | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Top Oncologypipeline Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant